JNJ ▼ -0.1% - Johnson & Johnson $JNJ - Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer Johnson & Johnson declined 0.1% today despite announcing positive trial results for RYBREVANT, its lung cancer treatment, which demonstrated the longest reported median overall survival in patients with EGFR exon 20 insertion mutations when combined with chemotherapy. The modest decline suggests investors may have already priced in positive efficacy data for the drug or were awaiting additional commercial or regulatory clarity beyond the survival findings. 13-SEP-2026 09:45 PM ET